Navigating an SLC35A2-CDG Diagnosis

Receiving a diagnosis of SLC35A2-CDG can feel overwhelming, especially since it is an ultra-rare condition that many doctors may not have encountered before ^[1]. This condition belongs to a group of disorders called Congenital Disorders of Glycosylation (CDG). These are metabolic diseases where the body has trouble adding sugar chains (glycans) to proteins or fats, which are essential for the body to function properly ^[2].

The Role of the Golgi and UDP-Galactose

To understand this condition, it helps to think of your child’s cells as a factory. One part of this factory, called the Golgi apparatus, acts like a packaging center where sugars are attached to molecules. For this to happen, the factory needs a steady supply of “building blocks.”

In SLC35A2-CDG, the “truck” that carries a specific activated sugar called UDP-galactose into the Golgi is broken ^[2]. Because the Golgi doesn’t get enough UDP-galactose, the cell cannot properly build certain complex fats and proteins, particularly gangliosides, which are vital for brain development and function ^[3]. This shortage of UDP-galactose in the Golgi is believed to be the primary cause of the neurological symptoms seen in this disorder ^[2][3].

Genetics: X-Linked, De Novo, and Recurrence Risk

This condition is linked to the X chromosome. However, in many cases, the genetic change is de novo, meaning it was a random event that occurred and was not inherited from either parent ^[3]. Families should still pursue individualized parental testing and recurrence-risk counseling, because variants can arise after conception, some cases are inherited, and parental germline mosaicism (where the variant is hidden in the egg or sperm cells) can affect the risk for future pregnancies.

You may also hear the term mosaicism. This means the genetic change is only present in some of the body’s cells and not others ^[4]. In some children, the variant might even be restricted to the brain, which can make it harder to detect through standard blood tests ^[5][6].

The Diagnostic Challenge: Normal Transferrin Tests

A major hurdle in diagnosing SLC35A2-CDG is that the most common screening test for CDG, called a serum transferrin glycosylation test, often comes back normal in these patients ^[3][7].

Transferrin is a protein made in the liver. Because the genetic defect in SLC35A2-CDG may affect the brain more severely than the liver, or because some cells function normally, the liver might still produce “normal-looking” transferrin ^[3]. Therefore, a normal result cannot be used to rule out this disease. Doctors often need to use advanced genetic sequencing or more specialized glycan testing to confirm the diagnosis ^[8][9].

Neurological Impact and Symptoms

SLC35A2-CDG is primarily a neurological disorder. While every child is different, common features include:

• Global Developmental Delay: Challenges in reaching physical and mental milestones ^[10].
• Epilepsy: Frequent seizures, which may begin in infancy as infantile spasms ^[10][11].
• Hypotonia: Low muscle tone, which can make a child feel “floppy” ^[10].
• Brain Imaging Findings: An MRI may show signs like delayed myelination (the insulating coating on nerves) or a thin corpus callosum (the bridge between the two sides of the brain) ^[10].

Investigational Treatment: D-Galactose

There is currently no cure for SLC35A2-CDG, but there is a targeted, investigational dietary intervention using D-galactose, a simple sugar. The goal of this treatment is to provide the cells with enough extra galactose—which is converted inside cells to UDP-galactose—to increase available substrate and potentially overcome the transport defect ^[12].

In a small, uncontrolled study of 10 children, oral D-galactose supplementation showed promising but variable results:

• Developmental Progress: Five of the ten children resumed making developmental gains, such as improved head control or the ability to swallow better ^[12].
• Seizure Control: Some families reported a reduction in seizure activity, though seizure efficacy has not been fully established ^[12].
• Digestive Improvement: Improvements in gastrointestinal symptoms were also noted, while one patient had no clinical improvement ^[12].

In these studies, the sugar was generally well-tolerated, though some children experienced minor stomach discomfort that improved when the dose was adjusted ^[12][5]. It is critical that this therapy is only considered through an appropriate clinical or research pathway and monitored under the strict supervision of a metabolic specialist ^[12].